Bing Yao, Ph.D.
Bing Yao, Ph.D. is an accomplished executive and scientist with over 25 years of experience in the biotechnology and pharmaceutical industry. He is the Co-Founder and Chief Executive Officer of ArriVent Biopharma, a research and development company focused on globally developing top innovations from biotechnology hubs around the world. Prior to ArriVent, he served as Chairman and CEO of Viela Bio, which he co-founded in 2018. In 2021, Viela Bio was acquired by Horizon Therapeutics for $3 billion.
Bing was previously the Senior Vice President of Respiratory, Inflammation & Autoimmunity at MedImmune, a wholly owned subsidiary of AstraZeneca, where he led the development and approval of multiple novel biologics for autoimmune and respiratory indications. Before MedImmune, he was the head of Project Team Leaders (PTL) for immunology, neurosciences, virology, and metabolism at Genentech, and held key roles at Tanox, Aventis, and Amgen.
Bing received his Ph.D. in microbiology and immunology from the University of Iowa. He has authored more than 50 peer-reviewed publications and holds over 20 patents and patent applications.